Our CEO and Founder, Derek Gilroy, is Professor of Experimental Immunology and Head of Experimental & Translational Medicine at University College London (UCL). Derek has pioneered the concept of inflammation resolution as an attractive approach for the treatment of chronic disease - targeting key elements that actively block resolution pathways, rather than managing just the clinical symptoms of inflammation.
Derek Gilroy
CEO and Founder of PENTA
Derek brings his immunology and translational medicine expertise to lead our therapeutics discovery programmes for a new generation of pro-resolution therapeutics.
Konstantinos Thalassinos
Professor of Mass Spectrometry at UCL.
Expertise in the structure and dynamics of protein complex interactions. Unravelling molecular signalling pathways in patient tissues will drive our target identification and therapeutic MOA studies.
David Selwood
Professor of Biological & Medicinal Chemistry, at the Wolfson Institute for Biomedical Research, UCL.
David brings his extensive knowledge and experience in medicinal chemistry discovery programmes to our scientific advisory board.
Craig Southern
Craig Southern has an extensive background in immunology and oncology translational drug discovery programmes, working within academia, biotech & pharma. Craig will lead discovery, pharmacology and preclinical studies for our lead therapeutic candidates.
Muhammad Shipa
Consultant Rheumatologist, Lupologist, and BEAT-LUPUS trial investigator.
As a Principle Investigator at UCL, Shipa combines his clinical perspective with a bioinformatic approach to the analysis of specific disease endotypes.